Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

Main Inclusion Criteria: * Male or female patient aged between 18 and 55 years. * External condylomas, 1-15 lesions, non-confluent and individually isolated. * Lesions must not be internal (ie, they must not penetrate the urethral meatus, vagina or anal canal); their visualization must be complete by patients and investigators without major facilitation maneuvers and easily documented by digital pictures. * Lesions should have a total surface smaller than 5 cm2, and an individual surface smaller than 1 cm2; lesions should be easily measured using a "French Catheter Scale". * Lesions to be treated should have appeared between 1-6 months before screening and patients should not have received any previous condyloma treatment since their appearance. * For patients having previous episodes of condyloma lesions, they shouldn't have received any condyloma treatment for at least 12 months before screening. Main Exclusion Criteria: * Patients with any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious disease that, in the Investigator's judgment, prevents the patients from participating to the study. * Patients with VIN or PIN (intraepithelial neoplasia of vulva or penis; ie, Bowenoid papulosis), or genital disease (ie, lichen sclerosus, lichen planus, lichen simplex chronicus, dermatitis, psoriasis, bullous diseases, systemic diseases with genital manifestations) requiring treatment. * Patients with fibroepithelial polyps or scaly non-viral papillomas, seborrheic keratosis, follicular papules, syringoma, or circumscribed lymphangiomas. * Patients whose skin condition or coloration would interfere with the observation and the follow-up of the lesions during the study. * Patients for whom a proper follow-up of the lesions during the study will not be possible, because of hair growth in the treatment area.